Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pemigatinib in Advanced SDH-deficient GIST
NCT07434843Phase 2Recruiting
- Sponsor
- Dana-Farber Cancer Institute
- Start
- May 2026
- Primary completion
- Oct 2028
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 1
01
Overview
A Phase 2 trial of pemigatinib in gastrointestinal stromal tumor (GIST), sponsored by Dana-Farber Cancer Institute. Started May 2026; status: recruiting.
02
Drugs
pemigatinib
03
Conditions
gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on NCT07434843.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07434843.